ArticleFrontiers in neurology2025
The burden of motor neuron diseases in Asia, 1990-2021: temporal patterns and age-period-cohort analyses.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diverging trends in motor neuron disease burden in China: an ageing-driven increase despite declining age-standardised rates - a GBD 2021 analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Global, regional, and national trends in DALYs for blindness and vision loss in teenagers and young adults, 1990-2019: an age-period-cohort analysis based on the Global Burden of Disease Study 2019.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to characterize the temporal trends of motor neuron diseases (MNDs) burden in Asia from 1990 to 2021, estimate their age, period and cohort effects, and forecast the disease burden for the next 15 years. Methods: Data were obtained from the Global Burden of Disease study 2021. The average annual percentage change (AAPC) of MNDs incidence, prevalence, mortality and disability-adjusted life years (DALYs) in Asia from 1990 to 2021 were estimated by joinpoint regression analysis. Age, period and cohort effects on incidence and mortality of MNDs were also evaluated by the age-period-cohort analysis. The autoregressive integrated moving average model was used to forecast age-standardized incidence, prevalence and mortality rates of Asian MNDs in 2022-2036. Results: From 1990 to 2021, the age-standardized mortality and prevalence rates of Asian MNDs increased from 0.140 to 0.173/100,000, and from 2.134 to 2.187/100,000, respectively. While the age-standardized incidence rate in Asia decreased from 0.561/100,000 in 1990 to 0.478/100,000 in 2021. The AAPC in age-standardized incidence, prevalence, mortality and DALYs rates of MNDs in Asia were -0.508, 0.087, 0.649 and -0.045, respectively. The age-period-cohort analysis showed that, for mortality and incidence, the burden of MNDs increased with age. The period effect exhibited an initial decline followed by a subsequent resurgence. The cohort effect increased in the early birth cohort while declined in the recent birth cohort. By 2036, the prevalence and mortality of MNDs are projected to rise to 2.241/100,000 and 0.177/100,000, respectively, while incidence is projected to decline to 0.468/100,000. Conclusions: The age-standardized incidence rate of MNDs in Asia was reduced yet their age-standardized rates of prevalence and mortality increased. This trend is projected to persist into the foreseeable future. Given substantial population base and increasingly severe aging demographics in Asia population, a holistic strategy is required to ease the burden of MNDs in Asia and get better health results for Asian patients with MNDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.